Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CD38 | P28907 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099122 | 0.82 | EGFR (0.76) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL6186662 | 0.81 | EGFR (0.70) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8782234 | 0.79 | EGFR (0.62) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL6186962 | 0.78 | EGFR (0.58) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL6191298 | 0.77 | EGFR (0.61) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8871863 | 0.77 | EGFR (0.82) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL6188538 | 0.76 | EGFR (0.62) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL13755812 | 0.75 | EGFR (0.65) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL6190034 | 0.74 | EGFR (0.55) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL29350058 | 0.74 | EGFR (1.00) | EGFRERBB2MAPK1HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1142919-C | Quinazoline derivatives as antitumor agents | — | 2004-03-24 | — | — | CN | disclosed |
| CN-1211240-A | Quinazoline derivatives as antitumor agents | ZENECA LTD (GB) | 1999-03-17 | — | — | CN | disclosed |